Competition & Markets Authority
Medical device supplier resolves CMA concerns
The CMA has accepted a proposal from Stryker to sell its business in the UK total ankle prostheses market to resolve competition concerns.
Stryker Corporation (Stryker) and Wright Medical Group N.V. (Wright) both manufacture a range of orthopaedic products for patients requiring implants in their feet, ankles and hands. Following an initial Phase 1 investigation in June, the Competition and Markets Authority (CMA) was concerned that the £4.2 billion merger between the 2 companies would have a negative impact on vulnerable patients in the UK who need ankle replacements.
Stryker has now offered to sell off its global total ankle replacement product and assets to Colfax Corporation (Colfax) who will incorporate this into their subsidiary, DJO Global. The CMA is satisfied that this full structural divestment will address its competition concerns.
The CMA has been co-operating closely with the US Federal Trade Commission (FTC), which has also been reviewing the merger. In August, the CMA announced that it had agreed to extend its consideration of an acceptable divestment package in order to align with the FTC’s timing and ensure that the divestment package would be acceptable in both UK and US jurisdictions.
Joel Bamford, CMA Senior Director of Mergers, yesterday said:
Competition in the medical device sector is vital to improve patient treatments, particularly for medical products designed to help vulnerable people suffering from serious degenerative conditions.
The close cooperation with the FTC’s inquiry and early engagement with both companies has enabled Stryker to address our important concerns about this deal and has led to an outcome that works on a global basis.
The full text of the CMA decision will be published shortly on the Stryker/Wright merger inquiry case page.
For media enquiries, contact the CMA press office on 020 3738 6460 or firstname.lastname@example.org.
Latest News from
Competition & Markets Authority
Metallurgy firms abandon merger during CMA investigation19/01/2021 12:20:00
The CMA no longer intends to refer the merger of TTI and Tronox to an in-depth investigation, after Tronox’s announcement to abandon the deal.
CMA breaks up motor parts merger13/01/2021 12:20:00
The CMA will require TVS Europe Distribution to sell 3G in order to protect competition in the commercial vehicle and trailer parts sector.
CMA to investigate Google’s ‘Privacy Sandbox’ browser changes08/01/2021 14:25:00
The CMA has opened an investigation into Google’s proposals to remove third party cookies and other functionalities from its Chrome browser.
CMA to investigate NVIDIA’s takeover of Arm07/01/2021 12:20:00
The CMA is inviting interested third parties to provide initial views on the anticipated acquisition of Arm by NVIDIA.
Metallurgy buyout raises competition concerns05/01/2021 09:10:00
The CMA has found that Tronox’s anticipated purchase of TTI raises competition concerns in the supply of chloride slag and titanium dioxide pigment.
CMA secures affordable supply of key bipolar drug21/12/2020 10:20:00
The CMA has accepted legally binding commitments from Essential Pharma to continue supplying a key bipolar drug at an affordable price for at least 5 years.
CMA publishes final report in funerals market investigation21/12/2020 09:20:00
The CMA has published the final report on its in-depth market investigation into funeral services, confirming its remedies for the sector.
Construction suppliers fined £15m for breaking competition law18/12/2020 12:20:00
The CMA has fined 2 major suppliers to the construction industry more than £15m for illegally colluding to reduce competition and keep prices up.